OXIDATIVE PREPARATION OF A-NOR-17 BETA-CARBOXY-3,5-SECOANDROSTAN-5-ONE-3 OIC ACID

Abstract: The present invention is an oxidative process for the conversion of 21-unsaturated progesterones (I) to the corresponding 3,5-secoandrost-5-one-3,17 beta -dioic acids (II) by use of either ozone or an oxidizing agent, which are useful intermediates in the production of DELTA <5>-4-aza-17-carbonyl steroids (III) which are useful in production of 5 alpha -4-aza amide (IV) pharmaceuticals. Also disclosed are the novel 21-unsaturated progesterones (I-C) and 3,5-secoandrost-5-one-3,17 beta -dioic acids (II-C).

Description: Oxidative preparation of A-NOR-17 beta-carboxy-3,5-seco androstan-5-one-3 oϊc acid. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is an oxidative process for the conversion of 21-unsaturated progesterones to the corresponding ,5-secoandrost- 5-one-3 ,175-dioic acid. 2. Description of the Related Art- The 21-unsaturated progesterones (I) are known compounds, see J.A.C.S., 82, 1709 (1960) and US Patents 2,727,905 and 4,325,878. The oxidation of the steroid A-ring by ozone (O3) is known, see J.O.C. 23, 1787 (1958), US Patent 3,285,918 and European Patent Application 88300697.5 published 3 August 1988 as European Publica¬ tion Number 277,002 A2. The oxidation of the steroid A-ring by MnC^ " /IO " " is known, see J. Med. Chem., 27, 1690 (1984) and European Patent Application 88300697.5 published 3 August 1988 as European Publication Number 277,002 A2. The oxidation of a steroidal (.-■_ ■ -. enone side chain to the corresponding 17 / S-C00H by ozone has been reported, see J.A.C.S. 78, 1414 (1956). The cleavage of 1,3-dicarbonyls is known, see J.C.S. Chem. Comm. , 1055 (1968). However, the oxidation of an alkoxyoxalkyl to give a carboxylic acid has not been reported. The known methods of producing the 175-carboxylic-3,5-seco- androstanes required that the particular side chain desired in the secosteroid (II) be present in the starting material to be oxidized or to a group which following oxidation of the steroid A- ring could readily be converted to the desired γη side chain, see, for example, European Patent Application 88300697.5 published 3 August 1988 as European Publication Number 277.002 A2 on page 1167, lines 49-52. The process of the present invention differs from known methods because the one step process produces oxidation involving both ends of the steroid molecule in a simultaneous reaction. The use of glyoxylates as 1,3-dicarbonyls in an oxidation reaction is novel. SUMMARY OF INVENTION Disclosed is a process for the production of a 3,5-secoandros- tan-5-one-3,17/S-dioic acid of formula (II) where (A-I) R^ is α-R-]__ι :fi-R ] __* * where one of R__ ] _ and Rι__2 i- s -H and the other of Rχ. and R-L_2 is * " H > * " *F * ~ cl ' " Br - ' τ < -° R l-3 where R-j ^ .3 is -H or C-^-Cg alkyl, -SR- ] __3 where .3 is as defined above, R2 is -H:-H; (A-II) ] _ is -H:-H, R2 is α-R 2 .ι:3- 2_.2 where one of R2.1 and R 2-2 is " H and the otner °f R 2-l and R 2-2 is "H ' "F ' "c - 1 -' "Br* "I ' -OR 2 _3 where R 2 _3 is -H or C- j _-C 6 alkyl, -SR 2 .3 where R 2 .3 is as defined above; R 7 is is -H, -F, -Cl, -Br, -I, -OR-7..3 where R7.3 is -H or C-j ^ -Cg alkyl, and where R7..2 is ""-- ■ * " c - > " F > ~ C~ L > -Br, -I, -OR7. where R7.4 is -H or C^-Cg alkyl, -SR7.4 where R7.4 is as defined above, with the proviso that one of R7.1 and 7.2 i -H; (C-I) R; is α-H.β-O-, where β-0- is taken together with R9 to form an epoxide between C9 and C- ; (C-II) R 9 is -H, -F or -Cl and RJ_-J_ is =0 or α.-H: -R- j _-j__-*_ where R ll-1 is "H or "0H ' R-j_g is α-R-j_g.-j_:β-R- L g.2 where one of R^g-i and g_2 -H and the other is -H, -OH and -CH3 which comprises (1) contacting a 21-unsaturated progesterone of formula (I) where R ] _, R , R7, R9, R ] _ } _ and R-^g are as defined above, and where R 22-l is * " H * -OH, C χ -C 6 alkyl, C4-C7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C- j _- C3 alkyl, -O 22-3 where R22-3 I s c l" c 3 alkyl, -N 22-4 R 22-5 where 22- 4 and R 22-5 are e same or different and are selected from the group consisting of -H, C-^-C^ alkyl and C4-C7 cycloalkyl, -O-R22-6 where R 22-6 ^- s t - ' l"" c 6 alkyl, C4-C7 cycloalkyl and -φ ; R 22-2 is - H > C- j _-C 6 alkyl, c - c 7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C**_- C3 alkyl, -OR22-7 where R22-7 I s < - ' l"'--'3 alkyl, -N 22-8 22-9 where R22- g and R22-9 are tne same or different and are selected from the group consisting of -H, C- ] _-C alkyl and C4-C7 cycloalkyl, • "°- R 22-10 where 22-10 I s ( - ' l"*--*6 alkyl, C4-C7 cycloalkyl and -Φ , -CO-O-R22-H where R 22-ll l* 3 -^l'^lO alkyl, C4-C7 cycloalkyl or -Φ optionally substituted with 1 thru 5 -N0 2 , -F, -Cl, -Br, -CN, C_- C3 alkyl, -OR22-I2 where 22-I2 -- s C l" c 3 alkyl, -N 22-13 R 22-14 where 22-13 and 22-14 are tne same or different and are selected from the group consisting of -H, C- j _-C4 alkyl with O3 , (2) contacting the reaction mixture of step (1) with an aqueous hydroxide or a means for generating hydroxide and (3) neutralizing the hydroxide with an acid. Also disclosed is a process for the production of a 3,5-seco- androstan-5-one-3,173-dioic acid of formula (II) where R- j _, R2, R 7 - R 9 ' ll and R 16 are as de i ne£ i above which comprises , (1) contacting a 21-unsaturated progesterone of formula (I) where R]_, R2, R7, R9, R n, 16 • R 22-l nd 22-2 are as de fi ne< i above, with an oxidizing agent. Further, disclosed are the 21-unsaturated progesterones (I-C) and 3 , 5-secoandrostan-5-one-3 , 17/5-dioic acids (II-C) which include the 21-unsaturated progesterones (I) and 3 , 5-secoandrostan-5-one- 3,17.-dioic acids (II) where the C-ring is an 9β ,ll -epoxide. DETAILED DESCRIPTION OF THE INVENTION The 21-unsaturated progesterones (I) are known compounds, see US Patents 2,727,905 and 4,325,878 and J.A.C.S. 82, 1709 (I960). Alternatively they can readily be prepared from known substituted progesterones by methods known to those skilled in the art, see, for example, US Patent 2,727,905 and Gazz. Chim. Ital. 84, 312 (1954). In CHART A and the claims, the C- j _ 7 side chain is set forth as -CO- CH=C(R22-l) ( 22-2- ) which when R 22-l i- s " ( - ) ^ s > as -*- s kno n to those skilled in the art, equivalent to -CH2-CO-R22-2• l fc * 5 preferred that R22-I is -° H and R 22-2 is -CO-O-R22-II 4 l z is Preferred that R 22-ll -*- s c l" c 4 alky . it i more preferred that R 22-ll I s ^1 or c 2 alkyl. There are two different ways to practice the process of the present invention. The first method involves contacting the 21- unsaturated progesterones (I), with O3 , followed by aqueous hydrox¬ ide, or a means for generating hydroxide, and then neutralizing the hydroxide with acid. The 21-unsaturated progesterones (I) need to be dissolved in an appropriate solvent or mixtures thereof. Suitable solvents include, methylene chloride, acetic acid, chloroform, methanol, ethanol, propanol, isopropanol, butanol, ethyl acetate, DMSO, acetone, dioxane, water and mixtures thereof depending on the particular 21-unsaturated progesterone (I) . The preferred solvent is a methylene chloride/acetic acid mixture. The ozonolysis is operable in a temperature range of about 0 to about -100°, preferably about -20 to about -80°, more preferably about -78°. While it is operable to add aqueous hydroxide to the reaction mixture, it Is preferred that the aqueous hydroxide be added in two steps. First, just water and then solid hydroxide. Means for generating hydroxide include, bicarbonate, carbonate or an amine. Amines, even those that are not very water soluble, generate hydroxide. They react with water, abstracting a proton from the water molecule generating an amine cation and hydroxide (anion) . The reaction of the amines (A) and water can be visualized as A + H2O ► A-H + + OH " . Operable amines include, for example, diethylamine, triethylamine, pyridine, aniline, piperazine, pyrrolidine, piperidine, morpholine, 1-methylpiperidine, Q-naphthylamine, imidazole and substituted imidazoles , 1,2,4-triazole and substituted 1,2,4-triazoles, benzimidazole and substituted ben- zimidazoles, and equivalents thereof. For example, if the amine was triethylamine or pyridine, the cation generated would be (CH3CH2)3NH + and pyridinium respectively along with hydroxide. It is preferred the hydroxide be sodium or potassium hydroxide. It is desirable to warm the reaction mixture either before or after the addition of the aqueous base to prevent the reaction mixture from freezing as is known to those skilled in the art. It is preferred to warm the reaction mixture to about 0° . When the 21-unsaturated progesterone (I) is contacted with O3 the contacting is effectuated by bubbling/sparging O3 gas thru a solution of the 21-unsaturated progesterone (I) . While the reaction will proceed with less than 2 equivalents of O3, it is preferred that at least 2 equivalents of O3 be used since that amount is required for the reaction to go to completition. Any large excess is not harmful, just wasteful. As a practical matter the reaction mixture is contacted with somewhat greater than 2 equivalents. It is preferred to remove the excess O3 from the reaction mixture prior to contacting with aqueous hydroxide. The O3 is removed by sparging with oxygen, and then the oxygen is removed by sparging with an inert gas such as nitrogen. If the excess O3 is removed, prior to contact¬ ing with the aqueous hydroxide, then it is preferred to contact the reaction mixture with H2O2 prior to contacting the reaction mixture with the aqueous hydroxide. Following the addition of the aqueous hydroxide, the excess hydroxide is neutralized by the addition of an acid. Since the only purpose of the acid is to neutralize the hydroxide virtually any moderately strong or strong acid is operable. Preferred acids are hydrochloric, sulfuric, phosphoric, nitric, acetic, perchloric, trifluoroacetic, citric, succinic, maleic, benzoic and p-TSA, more preferred are sulfuric and hydrochloric. Using the second method, the 21-unsaturated progesterones (I) are dissolved in an appropriate solvent, as discussed above, and contacted with an oxidizing agent. The first type of oxidizing agent consists of an oxidant or means of generating the oxidant. The oxidant is selected from the group consisting of RUO4, persulfate, pervanadate, pertungstate or Mnθ4" . This oxidant can be used stoichiometrically, or preferably, it is used catalytically with a means for producing the oxidant, a reoxidant. Means for producing the oxidant include is selected from the group consisting of NaOCl, NaClθ , IO ή " ! and Ca(0Cl)2. Even catalytic amounts of the oxidant are operable provided 4 or more equivalents of the means for generat¬ ing the oxidant (reoxidant) are present as is more fully discussed below. Alternatively, the oxidizing agent is a two stage oxidant. With the two stage oxidants, it is believed the first oxidant oxidizes the 21-unsaturated progesterone (I) to a glycol and the second oxidant cleaves the glycol. The two stage oxidants include, for example, 0s0 4 /Pb(0Ac)4, KMnθ /Pb(OAc) , OSO4/IO4 '1 . The preferred two stage oxidants include osmium tetroxide followed by periodate or lead tetraacetate, and permanganate followed by periodate. The oxidation reaction using the oxidizing agent is operable in a temperature range of about -100 to about 65° , preferably about -80 to about 40° . The reaction requires a total of 4 equivalents of the oxidizing agent. If catalytic amounts of the oxidant are used, then 4 equivalents of the reoxidant (such as 104 " !) are required. Alternatively, if 2 equivalents of the oxidant (for example, OSO ) are used then 2 equivalents of the reoxidant (for example, 10 " !) are required. The reaction will proceed with less than 4 equivalents of the oxidizing agent but not to completion. It is therefore preferred that at least 4 equivalents of the oxidizing agent or a means for generating be used. It is preferred that following the contacting of the 22-satura- ted progesterone (I) with the oxidizing agent, that aqueous hydroxide be added. While it is operable to add aqueous hydroxide to the reaction mixture, it is preferred that the aqueous hydroxide be added in two steps. First, just water and then solid hydroxide. Means for generating hydroxide include, bicarbonate, carbonate or an amine. It is preferred the base be sodium or potassium hydroxide. Following the addition of the aqueous hydroxide, the excess hydroxide is neutralized by the addition of an acid. Virtually any moderately strong or strong acid is operable. Preferred acids are hydrochloric, sulfuric, phosphoric, nitric, acetic, perchloric, trifluoroacetic, citric, succinic, maleic, benzoic and p-TSA. It is desirable to warm the reaction mixture either before or after the addition of the aqueous base to prevent the reaction mixture from freezing as is known to those skilled in the art. It is preferred to warm the reaction mixture to about 0° . The final product, the seco-steroid (II) is extracted into a variety of organic solvents. Preferred is ethyl acetate or methylene chloride. If methylene chloride is used the seco-steroid (II) can be converted to the 4-aza steroids directlv. If it is desired to crystallize the seco-steroid (II) , it is preferred to use ethyl acetate for Isolation. The seco-steroid (II) is useful in producing Δ -4-aza-17- carbonyl steroids (III) which are transformed to 5c_-4-aza amides (IV), useful pharmaceuticals, all by means well known to those skilled in the art, see, for example, European Patent Application 88300697.5 published 3 August 1988 as European Publication Number 277,002 A2, US Patents 4,325,878 and 4,377,584, J. Steroid Biochem. , 19, 385 (1983), J. Med. Chem., 27, 1690 (1984). With the Δ 5 -4-aza- 17-carbonyl steroids (III) R4 is -H or C-L-C4 and R Q is -OH (acid), -OR20-I (esters) where R20-I i s c l' c 4 alkyl or -φ , and -NR20- 20-3 (amides) where R20-2 ano - 20-3 are -h& same or different and are -H or C- j _-C 3 alkyl. DEFINITIONS AND CONVENTIONS The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims. I. CONVENTIONS FOR FORMULAS AND DEFINITIONS OF VARIABLES The chemical formulas representing various compounds or molecu- lar fragments in the specification and claims may contain variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a numerical subscript, for example, "Z^" or "R^" where "i" is an integer. These variable substituents are either monovalent or bivalent, that is, they represent a group attached to the formula by one or two chemical bonds. For example, a group Z ] _ would repres¬ ent a bivalent variable if attached to the formula CH3-C(-=Z_)H. Groups R^ and RJ would represent monovalent variable substituents if attached to the formula CH3-CH 2 -C(RJ;) (R.*)H 2 . When chemical formulas are drawn in a linear fashion, such as those above, variable sub¬ stituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis. When two or more consecutive variable substituents are enclosed in parentheses, each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses. Thus, in the formula above, both R^_ and R.* are bonded to the preceding carbon atom. Also, for any molecule with an established system of carbon atom numbering, such as steroids, these carbon atoms are designated as C^_, where "i" is the integer cor¬ responding to the carbon atom number. For example, Cg represents the 6 position or carbon atom number in the steroid nucleus as tradition¬ ally designated by those skilled in the art of steroid chemistry. Likewise the term "Rg" represents a variable substituent (either monovalent or bivalent) at the Cg position. Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain. The symbol "-" in general represents a bond between two atoms in the chain. Thus CH -O-CH2- CH(R^)-CH3 represents a 2-substituted-1-methoxypropane compound. In a similar fashion, the symbol "=" represents a double bond, e.g., CH2=C(R^ -O-CH3, and the symbol "≡" represents a triple bond, e.g., -CH2-CH3. Carbonyl groups are represented in either one of two ways: -CO- or -C(=0)-, with the former being preferred for simplicity. Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion. Thus, the compound 4-chloro-2-methylpyridine can be represented in linear fashion by N*=C(CH3)-CH=CC1-CH=C*H with the convention that the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring. Likewise, the cyclic molecular fragment, 4- (ethyl)-1-piperazinyl can be represented by -N - -CH2- C*H 2 . A rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound. For saturated compounds which have two substituents attached to a carbon atom which is part of a cyclic system, -C(X^)(X2)- the two sub- stituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial. However, the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other. In chemical structural formulas depicting such compounds, a substituent (X-^) which is "below" another substituent (X2) will be identified as being in the alpha (α) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -" or "...". The corresponding substituent attached "above" (X2) the other (X-^ is identified as being in the beta (β) configuration and is indicated by an unbroken line attachment to the carbon atom. When a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable. For example, a variable R^ attached to a carbon atom as- C(=R. j _)- might be bivalent and be defined as oxo or keto (thus forming a carbonyl group (-CO-) or as two separately attached monovalent variable substituents and β-R±. ] , - When a bivalent variable, R^, is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form "α-R^.- 4 '- β~R - ]r " or some variant thereof. In such a case both are attached to the carbon atom to give -C(α-R _ 1) (3- i.k - • For example, when the bivalent variable Rg, -C(=Rg)- is defined to consist of two monovalent variable substit- uents, the two monovalent variable substituents are α-Rg_- ] _: .-Rg_2, α-R 6 . 9 :/3-Rg. 10 , etc, giving -Ctα-R ^ ( -Rg_ 2 )- -C( -Rg_ 9 ) two monovalent variable substituents are α- n.χ:5- ii-2• For a r i n S substituent for which separate a and β orientations do not exist (e.g. due to the presence of a carbon carbon double bond in the ring) , and for a substituent bonded to a carbon atom which is not part of a ring the above convention is still used, but the α and β designations are omitted. Just as a bivalent variable may be defined as two separate monovalent variable substituents, two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable. For example, in the formula -C-^(R )H-C2 R- j )H- (C- j _ and C2 define arbitrarily a first and second carbon atom, respectively) R^ and Ri may be defined to be taken together to form (1) a second bond between C-^ and C2 or (2) a bivalent group such as oxa (-0-) and the formula thereby describes an epoxide. When R^ and RJ are taken together to form a more complex entity, such as the group -X-Y- , then the orientation of the entity is such that C-*_ in the above formula is bonded to X and Z< is bonded to Y. Thus, by convention the designa¬ tion "... Ri and Rj are taken together to form -CH2-CH2-O-CO- ..." means a lactone in which the carbonyl is bonded to C2. However, when designated "... Rj and R^ are taken together to form -CO-O-CH2-CH2- the convention means a lactone in which the carbonyl is bonded to C- j _. The carbon atom content of variable substituents is indicated in one of two ways. The first method uses a prefix to the entire name of the variable such as "C- j _-C4", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable. The prefix is separated from the variable by a space. For example, "C ] _-C4 alkyl" represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given) . Whenever this single prefix is given, the prefix indicates the entire carbon atom content of the variable being defined. Thus C2-C4 alkoxycarbonyl describes a group CH3-(CH2) n -0- C0- where n is zero, one or two. By the second method the carbon atom content of only each portion of the definition is indicated separately by enclosing the "C j _-C j " designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined. By this optional convention (C- j _- C3)alkoxycarbonyl has the same meaning as C2-C alkoxycarbonyl because the "C-^-C " refers only to the carbon atom content of the alkoxy group. Similarly while both C2-Cg alkoxyalkyl and (C-*_-C3)alk- o (C* j _-C3)alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms. II. DEFINITIONS All temperatures are in degrees Centigrade. O3 refers to ozone. Hydroxide refers to OH "l and when the term is used in the specification and claims it includes a means for generating hydrox¬ ide. -φ refers to phenyl. DMSO refers to dimethylsulfoxide. Pharmaceutically acceptable refers to those properties and/or substances which ' are acceptable to the patient from a pharmaco- logical/toxicological point of view and to the manufacturing pharma¬ ceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, solubility, patient acceptance and bioavailability. When solvent pairs are used, the ratios of solvents used are volume/volume (v/v) . EXAMPLES Without further elaboration, it is believed that one skilled In the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques. PREPARATION 1 21-Benzylidenepregn-4-ene-3,20-dione (I) Progesterone 3-methyl enol ether is slurried in methanol (13 ml) and benzaldehyde (3.4 ml) Is added. Sodium methoxide (25% wt/wt in methanol, 13 ml) is added, the mixture heated under reflux for 2 hr. and then cooled to 20-25°. The pH is adjusted to 1 by the addition of hydrochloric acid (6N, 15 ml) and the mixture stirred at 30° for 2 hr. Water (30 ml) is added and the mixture filtered to give the title compound. EXAMPLE 1 3,5-Secoandrost-5-one-3,17/3-dioic acid (II) 21-oxalylpregn-4-ene-3,20-dione methyl ester [I, Gazz. Chim. Ital., 84, 312 (1954), 20 g] is dissolved in methylene chloride (100 ml). Acetic acid (3.4 g) is added and the mixture is cooled to < -70° . Ozone is sparged through the mixture until excess ozone is present as indicated by a green color. Oxygen is then sparged until the excess ozone is removed and then nitrogen is sparged until the oxygen is .removed. The mixture is then warmed to 0° and water (24 ml) is added. After the mixture warms to 20° hydrogen peroxide (30%, 5 ml) is added and the mixture stirred for 1 hr. Sodium hydroxide (10%, 50 ml) is added. The pH is adjusted to 2 by the addition of concentrated sulfuric acid (16 ml) and methylene chloride is added to dissolve the product. The organic mixture is washed with water (2 x 50 ml) and concentrated (about 40 ml) . The solvent is exchanged to ethyl acetate (40 ml) , the mixture cooled to 0° and then hepatane (100 ml) is added to crystallize the title compound, mp 197.3-202.6°. EXAMPLE 2 3,5-Secoandrost-5-one-3,17^-dioic acid (II) 21-Benzylidenepregn-4-ene-3,20-dione (I, PREPARATION 1, 20 g) is dissolved in methylene chloride (80 ml) and methanol (20 ml) . The solution is cooled to -60° and ozone added until an excess is present, as indicated by a light blue color. Water (10 ml) is added and the solution warmed to 20-25°. The resulting solution is extracted with aqueous sodium hydroxide (5%, 100 ml). The aqueous solution is acidified to pH 2 by addition of hydrochloric acid (50%) and ex¬ tracted with ethyl acetate (100 ml) . The organic phase is dried over sodium sulfate and concentrated to 40 ml by distillation under reduced pressure. The mixture is cooled to 0° for one hr and the product collected by filtration to give the title compound, mp 203- 205°. EXAMPLE 3 3,5-Secoandrost-5-one-3,17^-dioic acid (II) A solution of 21-oxalylpregn-4-ene-3,20-dione methyl ester (I, 7.88 g) in methylene chloride (20 ml) and methanol (5 ml) is cooled to -40° and ozone added until an excess is present as indicated by the presence of a light blue color. Aqueous potassium carbonate (10%, 20 ml) is added and the mixture warmed to 20-25°. The phases are separated and the aqueous phase acidified to pH 2 by addition of aqueous sulfuric acid (10%). The mixture is extracted with ethyl acetate (50 ml) . The organic phase is concentrated to dryness to provide the title compound, mp 192-208°. EXAMPLE 4 3,5-Secoandrost-5-one-3,17^-dioic acid (II) A solution of potassium carbonate (5.5 g in 25 ml of water) is added to a solution of 21-oxalylpregn-4-ene-3,20-dione methyl ester (I, 3.9 g) in t-butanol (100 ml). A solution of sodium metaperiodate (3.0 g In 20 ml of water) is prepared and 2 ml of this solution is added in one portion to the steroid solution. A solution of potas¬ sium permanganate (0.6 g in 30 ml of water) is prepared and 10 ml is added to the steroid solution. The reaction mixture is kept at 40° during the reaction. The remaining periodate and permanganate solutions are added dropwise over 30 min. After stirring at 40° for 3 hr after the additions are complete the mixture is filtered through celite and enough sodium bisulfite added to discharge the pink color. The mixture is then concentrated to half volume under, reduced pres¬ sure and extracted with ethyl acetate (50 ml) . The organic phase is dried and concentrated to 10 ml volume and cooled. The product crys¬ tals are collected by filtration to give the title compound, 193- 201°. EXAMPLE 5 3,5-Secoandrost-5-one-3,17^-dioic acid (II) A solution of ruthenium tetroxide (RUO4) is prepared by suspend¬ ing ruthenium dioxide (Ruθ2, 0.169 g) in acetone (10 ml) and adding a solution of sodium metaperiodate (2.5 g in 10 ml of water). A solu¬ tion of 21-oxalylpregn-4-ene-3,20-dione methyl ester (I, 1.0 g) in acetone (10 ml) is added dropwise to the ruthenium tetroxide solu¬ tion. As the solution changes color from yellow to black, a solution of sodium metaperiodate (2.5 g in 10 ml of water) is added to main¬ tain the yellow color. After 4 hours the excess ruthenium tetroxide is is reacted by the addition of isopropanol. The mixture is filtered through celite and concentrated under reduced pressure to remove the acetone. The product is then extracted with ethyl acetate (20 ml) . This solution is then dried over sodium sulfa e and concentrated to dryness to give the title compound, mp 189-203°. CHART A CH-C(R 21 . 1 )(R 21 . 2 ) 15 25 CHART A (continued) (IV) CHART B CH-C ( R 21 . 1 ) ( R 21 . 2 ) 15 20 25

Claims: CLAIMS 1. A process for the production of a 3,5-secoandrostan-5-one-3,17/.- dioic acid of formula (II) where (A-I) R-^ is a-R;*__-*_: -R-L_ 2 where one of R ] _-i and R-j__ 2 i -H and the other of . and Rχ. 2 is -H, -F, -Cl, -Br, -I, -0R- j __3 where R- j __3 is -H or C-^-Cg alkyl, -SR- j __3 where Rχ.3 is as defined above, R 2 is -H:-H; (A-II) R-^ is -H:-H, R 2 is a-R2. \ : β-R2 - 2 where one of R 2 -l and R 2-2 is " H and the other of R2-I and R2-2 is -H, - F > -Cl, -Br, -I, -OR2.3 where R2-3 is -H or C- j _-Cg alkyl, -SR 2 _3 where 2-3 i as defined above; R 7 is α-R7_. 1 :y9-R 7 _2 where , is -H, -F, -Cl, -Br, -I, -OR7.3 where R7.3 is -H or C^-C alkyl, and where 7.2 is -H, -CH3, -F, -Cl, -Br, -I, -OR7.4 where R7.4 is -H or C- j _-Cg alkyl, -SR7.4 where R7.4 is as defined above, with the proviso that one of 7.1 and R7.2 i* 3 -H; (C-I) R* j _- j _ is a-rl: β-0- , where β-0- is taken together with Rq to form an epoxide between C9 and C;•_- ■ _; (C-II) R 9 is -H, -F or -Cl and R-•_ ■■ _ is =0 or α-H.^- - .i where R n-ι is - H or -° H ; R_g is α-R-j_g_ :^-R .2 where one of Rχg. and Rχ -2 i -H and the other is -H, -OH and -CH3 which comprises (1) contacting a 21-unsaturated progesterone of formula (I) CH-C(R 21 . 1 )(R 21 . 2 ) (I) where R- j _, 2, R , R9, Rτ_ι_ and R- j _g are as defined above, and where R 22-l -- s " " ** * • -OH, C- j^ -Cg alkyl, C4-C7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C ] _- C3 alkyl, -OR 22 .3 where R 2 2-3 i- 3 c l" c 3 alkyl, -NR 2 2-4 R 22-5 where 22-4 and 22-5 are t * ιe same or different and are selected from the group consisting of -H, C1-C4 alkyl and C4-C7 cycloalkyl, -0-R 22 _g where R 2 -6 I s c l" c 6 alkyl, C 4"" G 7 cycloalkyl and -φ R 22-2 is * " H - C ] _-Cg alkyl, C4-C7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C- j _- C3 alkyl, -OR 2 _7 where R 2 2-7 I- 3 ^l'^3 alkyl, -NR22-8 R 22-9 where R 22-8 and 22-9 are t ^ ιe same or different and are selected from the group consisting of -H, C1-C alkyl and C4-C7 cycloalkyl, -0-R 2 2-lo where 22-IO ^ s c - : l"" ( -'6 a lkyl, t - 4 4"C'7 cycloalkyl and -φ , -C0-0-R 2 .-j_ι where 2-H is ^1-^ 0 alkyl, C4-C7 cycloalkyl or -φ optionally substituted with 1 thru 5 -N0 2 , -F, -Cl, -Br, -CN, C- j _- C3 alkyl, -0 2 -12 where R22-12 I s < *- ; l" * --'3 alkyl , -N 22-13 22-14 where 22-13 and 22-1 are the same or different and are selected from the group consisting of -H, C- j _-C4 alkyl with O3, (2) contacting the reaction mixture of step (1) with an aqueous hydroxide or a means for generating hydroxide and (3) neutralizing the hydroxide with an acid. 2. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 1 where R 2 2-l I s * " υ H and 22-2 s -CO-O-R22-H where 22-ll I s ^1'^k alkyl. 3. A process for the production of a 3,5-secoandrostan-5-one-3,17/?- dioic acid (II) according to claim 1 where the aqueous hydroxide is added in two steps, first water followed by the hydroxide. 4. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (II) according to claim 1 where the hydroxide is generated from bicarbonate, carbonate or an amine. 5. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (II) according to claim 1 where any excess O3 is removed prior to addition of the aqueous hydroxide. 6. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 5 where H 2 0 2 is added following removal of the excess O3 and prior to contacting with aqueous hydroxide. 7. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (II) according to claim 1 where the reaction mixture is warmed before the addition of the aqueous hydroxide. 8. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 1 where the reaction mixture is warmed after the addition of the aqueous hydroxide. 9. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 1 where at least 2 equivalents of O3 are used. 10. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 1 where the acid is selected from the group consisting of hydrochloric, sulfuric, phosphoric, nitric, acetic, perchloric, trifluoroacetic, citric, succinic, maleic, benzoic and p-TSA. 11. A process for the production of a 3,5-secoandrostan-5-one-3,17;3- dioic acid of formula (II) where (A-I) R- ] _ is α-R- ] __- ] _: 3-R- j _.. where one of R . and Rχ.2 i *" H and the other of R .χ and R]__2 is -H, -F, -Cl, -Br, -I, -OR .3 where R .3 is -H or C -Cg alkyl, -SR- j __3 where R .3 is as defined above, R 2 is -H:-H; (A-II) R]_ is -H:-H, R2 is α-R2. '- β'^-2 - 2 where one of 2 -l an d R 2-2 -*- s "-^ and t ^ rιe other of R 2 -l a nd R 2 . is -H, -F, -Cl, -Br, -I, -OR2.3 where 2 -3 is -H or C-^-Cg alkyl, -SR2.3 where R 2 -3 i as defined above; R 7 is α-R 7 . 1 :/3-R 7 _2 where R 7 _.τ_ is -H, -F, -Cl, -Br, -I, -OR 7 _-j where R 7 _3 is -H or C-^-Cg alkyl, and where R7-2 is -H, -CH , -F, -Cl, -Br, -I, -OR7.4 where R7.4 is -H or C- j _-Cg alkyl, -SR _4 where R-7.4 is as defined above, with the proviso that one of R 7 . and R7_ is -H; (C-I) R-*_-*_ is α-H: 3-0-, where β-0 - is taken together with R9 to form an epoxide between Cg and C-*_- ■ _; (C-II) R9 is -H, -F or -Cl and R- is =0 or α-H:9-R- ] _ ] _.- ] _ where R ii- i is _H or * 0H ; R]_g is Q - i6-l : 9- R i6-2 where one of Rχg.χ and R]_g_2 is -H and the other is -H, -OH and -CH3 which comprises (1) contacting a 21-unsaturated progesterone of formula (I) CH-C(R 21 . 1 )(R 21 . 2 ) where R , R , R , R9 , R x and R-^g are as defined above , and where R 22 -l is " H < -OH , Cχ-Cg alkyl, C4-C7 cycloalkyl, -φ optionally substituted with 1-5 -NO2, -F, -Cl, -Br, -CN, C-j_- C3 alkyl, -OR22-3 where R 22 _3 is C-j_-C3 alkyl, -N 22-4 R 22-5 where R22- 4 and R 22-5 are t ^ ιe same or different and are selected from the group consisting of -H, C- | _-C4 alkyl and 04-0-7 cycloalkyl, -O-R22-6 where R22-6 I s c l" c 6 a lkyl, c 4" c 7 cycloalkyl and -φ ; R 22-2 is - H ' C l -C 6 alkyl, ' " C4-C7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C ] _- C3 alkyl, -OR22-7 where 22 -I I s ^ '^ > a lkyl, -NR22-8 R 22-9 where R22- g and 22-9 are t ^ ιe same or different and are selected from the group consisting of -H, C-L-C4 alkyl and C4-C-7 cycloalkyl, -O-R22- O where 22-X0 ^ s < -'I""--'6 a k • ^k'^1 cycloalkyl and -Φ . -CO-0-R 22 . 1 -ι_ where 2 2-ll is C I"" C 10 alkyl. c 4*- c 7 cycloalkyl or -φ optionally substituted with 1 thru 5 -N0 2 , -F, -Cl, -Br, -CN, C- j _- C3 alkyl, -OR22-I2 where R 2 2-12 -*- s c l" ( - ; 3 a l yl, -N R 22-13 22-14 where R 22-13 anα - 22-14 are t - :e same or different and are selected from the group consisting of -H, C - alkyl with an oxidizing agent. 12. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (II) according to claim 11 where R22-I i s ""0^ and R 22-2 ^ s -C0-0-R 2 χ.χχ where 2χ.χχ is Cχ-C4 alkyl. 13. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 11 where the oxidizing agent (1) is an oxidant or a means for generating the oxidant or (2) is two stage oxidants. 14. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 13 where the oxidant is RUO , persulfate, pervanadate, pertungstate or θ4 ~ . 15. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 13 where the means for generating the oxidant is selected from the group consisting of NaOCl, NaClθ , I04 "1 and Ca(0Cl) 2 . 16. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 13 where the two stage oxidents are selected from the group consisting of Osθ4/Pb(OAc)4, K θ4/- 17. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (I) according to claim 11 where aqueous hydroxide or a means for generating hydroxide is added following the contacting with the oxidizing agent. 18. A process for the production of a 3,5-secoandrostan-5-one-3,173- dioic acid (II) according to claim 11 where aqueous hydroxide is added in two steps, first water followed by the hydroxide. 19. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 11 where the hydroxide is generat¬ ed from bicarbonate, carbonate or an amine. 20. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 11 where the reaction mixture is warmed before the addition of the aqueous hydroxide. 21. A process for the production of a 3,5-secoandrostan-5-one-3,17 / 3- dioic acid (II) according to claim 11 where the reaction mixture is warmed after the addition of the aqueous hydroxide. 22. A process for the production of a 3,5-secoandrostan-5-one- * 3,17/3- dioic acid (II) according to claim 17 where the aqueous hydroxide is neutralized by acid. 23. A process for the production of a 3,5-secoandrostan-5-one-3,17/3- dioic acid (II) according to claim 11 where the acid is selected from the group consisting of hydrochloric, sulfuric, phosphoric, nitric, acetic, perchloric, trifluoroacetic, citric, succinic, maleic, benzoic and p-TSA. 24. A process for the production of a 3,5-secoanάrostan-5-one-3,173- dioic acid (II) according to claim 11 where at least a total of 4 equivalents are used of the oxidizing agent. 25. A 3,5-secoandrostan-5-one-3,173-dioic acid of formula (II-C) COOH where (A-I) Rx is ct-R- ] _. :/3-Rχ_2 where one of Rχ.χ and Rχ_2 is -H and the other of Rχ.χ and Rχ_2 is -H, -F, -Cl, -Br, -I, -ORχ.3 where R^_3 is -H or Cχ-Cg alkyl, -SR- j __3 where Rχ.3 is as defined above, R 2 is -H:-H; (A-II) R-]_ is -H:-H, R 2 is α-R 2 _χ: 3-R2_2 where one of R 2- .χ and R 2 _2 is -H and the other of R 2 .χ and R 2 _2 i -H, -F, -Cl, -Br, -I, -OR2.3 where 2.3 is -H or C- ] _-Cg alkyl, -SR 2 _3 where R 2 -3 is as defined above; R 7 is α-R7. :/3-R 7 .2 where R 7 _- j _ is -H, -F, -Cl, -Br, -I, -OR 7 _ 3 where R 7 . 3 is -H or C- j _-Cg alkyl, and where R 7 . 2 is -H, -CH3, -F, -Cl. -Br, -I, -0R _4 where R 7 _4 is -H or C- j _-Cg alkyl, -SR 7 _4 where R7.4 is as defined above, with the proviso that one of R 7 .χ and R 7 _2 is -H; R-^ is Q - χ6-X : /S- X6-2 where one of Rχg.χ and R .2 I s "H an d the other is -H, -OH and -CH 3 . 26. A 2X-unsaturated progesterone of formula (I-C) CH-C(R 21 . 1 )(R 21 . 2 ) (I-C) where (A-I) R ] _ is α-R . ] _:^-R ] __2 where one of Rχ.χ and χ_2 i *" H and the other of Rχ.χ and Rχ_2 i -H, -F, -Cl, -Br, -I, -ORχ.3 where Rχ.3 is -H or C ] _-C alkyl, -SR-^.3 where Rχ.3 is as defined above, R 2 is -H:-H; (A-II) R- * _ is -H:-H, R 2 is α-R2_ :/3-R2-2 where one of 2-I ar *d 2-2 is -H. and the other of R2-X and R2-2 I s "" H > "" F > ""^1. -Br, -I, -OR 2 _3 where R2-3 is -H or C- j _-Cg alkyl, -SR2.3 where R2-3 is as defined above; R 7 is α-R 7 _.χ:θ-R 7 . 2 where R-/ . is -H, -F, -Cl, -Br, -I, -OR-7.3 where R 7 .3 is -H or C- j _-Cg alkyl, and where R 7 .2 is "H, -CH3, -F, -Cl, -Br, -I, -OR-7.4 where R 7 _4 is -H or C ] _-Cg alkyl, -SR 7 _4 where 7 _4 is as defined above, with the proviso that one of R 7 .χ and 7 _2 is -H; R^ is Q - χ6- :^- R 6-2 where one of χg.χ and Rχg_2 is -H an the other is -H, -OH and -CH3; R 22 -X is -H, -OH, c χ- c 6 al yl, C4-C cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, c l **c 3 alkyl, -OR22.3 where R 2 2-3 I- 3 C I * " C 3 alk y l, - R22-4 22-5 where R 22-4 and R 22-5 are t, e same or different and are selected from the group consisting of -H, Cι- C^ alkyl and C4-C-7 cycloalkyl, -0-R 2 2-6 where R22-6 s c l ' ^β alkyl, C4-C cycloalkyl and -Φ R 22-2 is *"H ' C- j _-Cg alkyl, c 4- c 7 cycloalkyl, -φ optionally substituted with 1-5 -N0 2 , -F, -Cl, -Br, -CN, C -C3 alkyl, -OR22-7 where 22 - I I s c l"- c 3 alkyl, -NR 2 2-8 R 22-9 where 22-8 and 22-9 are *- e same or different and are selected from the group consisting of -H, C- j _-C4 alkyl and C4-C7 cycloalkyl, " 0 " 22-10 where 22-10 I s c l" c 6 al yl, C 4"C7 cycloalkyl and -Φ , -CO-O-R22-XX where 2 2-X1 s < - ' l"'--"10 alkyl, C4-C7 cycloalkyl or -φ optionally substituted with 1 thru 5 -N0 2 , -F, -Cl, -Br, -CN, C * ]_-C3 alkyl, -OR 2 2-12 where R22-12 is C X" C 3 alkyl, " NR 22-13 R 22-14 where 22-13 and R 22-14 are the same or different and are selected from the group consisting of -H, C- j _-C4 alkyl. 27. A 21-unsaturated progesterone (IA) according to claim 26 where R 22-l is * " 0H and R 22-2 is -CO-0-R 2 2-iι where 2-H is c l"- c 4 alk y l.

Inventors: HERRINTON PAUL MATTHEW, HERRINTON, PAUL, MATTHEW
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1990
Main classification: C07J71
IPC codes: C07C51, C07C62, C07C323, C07D303, C07J71, C07J73